Advanced Management Strategies in Severe Asthma and COPD (MC)-COPD Phenotypes and Biologic Therapies ADRISH

COPD Phenotypes and Biologic Therapies ADRISH

Pdf Summary

The document focuses on Chronic Obstructive Pulmonary Disease (COPD), specifically exploring different phenotypes and endotypes, their pathophysiologies, and potential biologic therapies. COPD is a complex, heterogeneous disorder characterized by various phenotypes such as chronic bronchitis, emphysema, and asthma-COPD overlap. Traditional approaches to COPD have been largely uniform. However, understanding the specific phenotypes and endotypes—distinct biologic subclassifications based on molecular mechanisms—is essential for personalizing treatment.<br /><br />The text highlights eosinophil-predominant type-2 COPD, which affects 20-40% of patients. This form is driven by cytokines like IL-5, IL-4, and IL-13, unlike neutrophil-predominant COPD, which is more commonly associated with bacterial infections and acute exacerbations.<br /><br />Biological therapies are being studied for their potential benefits in specific COPD phenotypes. Dupilumab, a pioneering biologic therapy, has shown promise in treating eosinophil-predominant COPD, offering positive outcomes such as reduced exacerbation rates. Other biologics like Mepolizumab, Benralizumab, and Tezepelumab are being evaluated in clinical trials. Mepolizumab, targeting the IL-5 pathway, has shown favorable outcomes in reducing exacerbation rates in ongoing studies like MATINEE.<br /><br />Despite promising data for eosinophil-predominant COPD, treatments for neutrophil-predominant COPD remain less encouraging, though research continues actively. Upcoming trials, expected to conclude in 2025 and 2026, may provide further insights.<br /><br />In conclusion, understanding COPD's heterogeneity allows for more tailored therapies, potentially improving patient outcomes. Delivering biologic treatments based on specific phenotypes and endotypes holds promise for more effective management of COPD.

Keywords

COPD

Chronic Obstructive Pulmonary Disease

phenotypes

endotypes

biologic therapies

eosinophil-predominant

neutrophil-predominant

Dupilumab

Mepolizumab

cytokines

personalized treatment

COPD

Chronic Obstructive Pulmonary Disease